Outcomes after radioiodine ablation in patients with thyroid cancer: Long‐term follow‐up of a Chinese randomized clinicaltrial

Abstract

Two large randomized trials of patients with differentiated thyroid cancer (DTC) reported recently (HiLo and ESTIMABL1) found that the recurrence rate among patients who underwent 1.1\u2009GBq radioactive iodine (RAI) ablation was not higher than that of patients who underwent 3.7\u2009GBq radioactive iodine (RAI) ablation. However, no similar studies have been conducted in China. We aimed to report clinical outcomes in Chinese patients with low/intermediate risk of recurrence DTC after long‐term follow‐up, and evaluate the risk factors that influence the presence or absence of incomplete response at the final follow‐up.